Hologic (NASDAQ:HOLX) Issues Quarterly Earnings Results, Meets Estimates

Hologic (NASDAQ:HOLX) posted its quarterly earnings results on Monday. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01, Briefing.com reports. Hologic had a return on equity of 20.11% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter in the prior year, the firm posted $0.89 EPS. The company’s revenue for the quarter was up 4.5% on a year-over-year basis.

Hologic Price Performance

Shares of HOLX stock opened at $80.49 on Thursday. Hologic has a 1 year low of $66.93 and a 1 year high of $84.67. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The firm’s 50 day moving average is $81.05 and its 200-day moving average is $78.12. The firm has a market capitalization of $18.70 billion, a price-to-earnings ratio of 24.17, a PEG ratio of 3.03 and a beta of 0.98.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Leerink Partners cut their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Stephens reaffirmed an “overweight” rating and set a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Evercore ISI lifted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Mizuho lowered their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, Needham & Company LLC restated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Tuesday, October 15th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.25.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.